Docetaxel, Irinotecan, Recurrent, Refractory, Bone and Soft Tissue Sarcomas.

Trial Profile

Docetaxel, Irinotecan, Recurrent, Refractory, Bone and Soft Tissue Sarcomas.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Docetaxel (Primary) ; Irinotecan (Primary)
  • Indications Alveolar soft part sarcoma; Bone cancer; Chondrosarcoma; Clear cell sarcoma; Ewing's sarcoma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Nerve sheath neoplasms; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Sep 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 28 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top